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A B S T R A C T
Background
Preoperative radiotherapy (RT) decreases local recurrence rate and improves survival in stage II and III rectal cancer patients. The
combination of chemotherapy with RT has a sound radiobiological rationale, and phase II trials of combined chemoradiation (CRT)
have shown promising activity in rectal cancer.
Objectives
To compare preoperative RT with preoperative CRT in patients with resectable stage II and III rectal cancer.
Search methods
We searched the Cochrane Register of Controlled Trials, Web of Science, Embase.com, and Pubmed from 1975 until June 2012. A
manual search was performed of Ann Surg, Arch Surg, Cancer, J Clin Oncol, Int J Radiat Oncol Biol Phys and the proceedings of
ASTRO, ECCO and ASCO from 1990 until June 2012.
Selection criteria
Relevant studies randomized resectable stage II or III rectal cancer patients to at least one arm of preoperative RT alone or at least one
arm of preoperative CRT.
Data collection and analysis
Primary outcome parameters included overall survival (OS) at 5 years and local recurrence (LR) rate at 5 years. Secondary outcome
parameters included disease free survival (DFS) at 5 years, metastasis rate, pathological complete response rate, clinical response rate,
sphincter preservation rate, acute toxicity, postoperative mortality and morbidity, and anastomotic leak rate. Outcome parameters were
summarized using the Odds Ratio (OR) and associated 95% confidence interval (CI) using the fixed effects model.
Main results
Five trials were identified and included in the meta-analysis. From one of the included trials only preliminary data are reported. The
addition of chemotherapy to preoperative RT significantly increased grade III and IV acute toxicity (OR 1.68-10, P = 0.002) and
marginally affected postoperative overall morbidity (OR 0.67-1.00, P = 0.05) while no differences were observed in postoperative
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mortality or anastomotic leak rate. Compared to preoperative RT alone, preoperative CRT significantly increased the rate of complete
pathological response (OR 2.12-5.84, P < 0.00001) although this did not translate into a higher sphincter preservation rate (OR 0.92-
1.30, P = 0.32). The incidence of local recurrence at five years was significantly lower in the CRT group compared to RT alone (OR
0.39-0.72, P < 0.001). No statistically significant differences were observed in DFS (OR 0.92-1.34, P = 0.27) or OS (OR 0.79-1.14,
P = 0.58) at five years.
Authors’ conclusions
Compared to preoperative RT alone, preoperative CRT enhances pathological response and improves local control in resectable stage
II and III rectal cancer, but does not benefit disease free or overall survival. The effects of preoperative CRT on functional outcome
and quality of life are incompletely understood and should be addressed in future trials.
P L A I N L A N G U A G E S U M M A R Y
Radiotherapy alone versus radiotherapy combined with chemotherapy before operation of rectal cancer
Patients with cancer of the rectum, the end part of the large bowel immediately above the anus, are treated with surgery. When
the tumour is deemed to present a high risk of recurrence after surgery, a course of radiotherapy (RT) is administered before the
operation. It has been proven in clinical studies that this ’preoperative’ radiotherapy improves the outcome in rectal cancer patients.
Recently, several studies have investigated the combination of radiotherapy with chemotherapy (CRT) before surgery. In theory, adding
chemotherapy enhances the antitumour activity of radiotherapy. This meta-analysis has summarized the results of five studies that
compared preoperative RT alone with preoperative CRT in rectal cancer patients. All of these studies were randomized, which means
that the decision to administer either RT or CRT was determined by chance (ballot draw). The results of the meta-analysis may be
summarized as follows. Compared to RT alone, preoperative CRT leads to increased side effects during treatment. Also, postoperative
complications are somewhat increased, although the risk of dying from postoperative complications is similar. Preoperative CRT is
more effective in causing tumour shrinkage (downstaging), and in preventing local recurrence of the disease. However, addition of
chemotherapy did not result in more sphincter preserving surgeries, and did not affect the overall survival in rectal cancer patients.
B A C K G R O U N D
The incidence of fatal cases of colorectal cancer in Europe exceeds
200000 per year. Due to the specific anatomy and biology of rec-
tal cancer, surgery alone historically has been associated with local
recurrence in up to one in four patients. Locally recurrent dis-
ease is usually incurable, causes important morbidity and suffer-
ing and gives rise to systemic metastases. In the last few decades,
improvements in surgical technique have dramatically lowered the
incidence of locally recurrent disease. Careful pathological studies
have clearly demonstrated that the major cause of local recurrence
is the persistence of tumour foci within the mesorectum (Quirke
1986; Quirke 2003). Intact removal of the entire mesorectum (to-
talmesorectal excision orTME) in cancers of themid or lower third
of the rectum was pioneered by Heald and has resulted in local re-
currence rates lower than 5-10% (Heald 1982;Heald 1998; Enker
1999). The importance of complete removal of the surrounding
mesorectum necessitates precise preoperative evaluation of the cir-
cumferential resection margin using imaging. Recently, magnetic
resonance imaging (MRI) using a phased array coil has emerged as
the imaging modality of choice in the preoperative evaluation of
locally advanced rectal cancer (Beets-Tan 2003; Beets-Tan 2005;
Brown 2004; Daniels 2005; Brown 2006).
Parallel to improvements in surgical technique, adjuvant therapy
regimens have been tested in clinical trials in an effort to reduce
local recurrence rates. Neoadjuvant radiotherapy (RT) has been
shown to significantly decrease local recurrence rate and improve
survival provided a biologically equivalent dose (BED) of at least
30 Gy is administered (Gray 2001). The advantages of preopera-
tive over postoperative RT include enhanced effectiveness in well
oxygenated tissue, downstaging of advanced tumors and better
treatment compliance (Glimelius 2002). The theoretical superior-
ity of the preoperative approach over postoperative adjuvant ther-
apy has been confirmed in the recent German rectal cancer trial
(Sauer 2004). The effect of preoperative RT on local recurrence
rate is consistent even when optimal surgical technique (TME) is
implemented. This was demonstrated by the results of the Dutch
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rectal cancer trial which randomized rectal cancer patients to un-
dergo either RT followed by TME or TME alone in the setting of
a national surgical training programme (Kapiteijn 2001, Peeters
2007). Compared to TME alone, 5x5 Gray (Gy) of RT followed
by TME resulted in a significantly lower local recurrence rate, al-
though no improvement in overall survival (OS) was noted.
Although preoperative RT results in a complete pathological re-
sponse in a minority of patients, significant downsizing is rarely
achieved using short schedule RT regimens. In order to improve
tumour response, preoperative RT has been combined with che-
motherapeutic regimens. There is a strong radiobiological ratio-
nale to combine RT with chemotherapy. Combined chemoradia-
tion (CRT) for rectal cancer was introduced in the adjuvant setting
and subsequently in irresectable disease, where significant down-
sizing and downstaging was observed in many patients resulting
in achievement of a resectable status in some cases (Minsky 1993;
Minsky 1997). The argument for preoperative CRT in resectable
disease is based primarily on possible downsizing and downstag-
ing of tumors close to the circumferential resection margin or the
sphincter apparatus, thereby enhancing both R0 resection and the
sphincter preservation rate. The paramount importance of per-
forming the resection with a negative CRM was shown in several
clinical studies (Nagtegaal 2002). Secondly, the addition of che-
motherapy could eliminate microscopic systemic disease present
at the time of surgery. Possible concerns of preoperative CRT in-
clude an increase of both local and systemic toxicity and over
treatment of inaccurately staged patients (Ammann 2003). Sev-
eral phase I and II studies using preoperative CRT have shown a
promising tumour response with acceptable toxicity (Rodel 2003;
Osti 2004). A limited number of prospective randomized trials
comparing preoperative RT alone with preoperative CRT in re-
sectable rectal cancer are published or ongoing.
O B J E C T I V E S
To compare preoperative RT with preoperative CRT in patients
with resectable stage II or III rectal cancer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCT’s) which randomized patients
before surgery with curative intent to one of at least two schedules
of preoperative therapy including RT and CRT.
Types of participants
Patients with clinical stage II or III resectable rectal cancer under-
going preoperative RT or CRT followed by surgery.
Types of interventions
Preoperative RT or CRT using fractionated external radiotherapy
followed by surgery with curative intent (resectable rectal can-
cer). The surgical procedure must consist of rectal amputation or
sphincter preserving anterior resection using an open or laparo-
scopic approach; local excisions are excluded.
Types of outcome measures
Primary
- local recurrence rate at 5 years
Secondary
- overall survival at 5 years
- disease free survival at 5 years
- systemic metastasis rate
- pathological complete response rate
- clinical response rate
- sphincter preservation rate
- postoperative mortality within 30 days
- postoperative morbidity
- anastomotic leak rate
Search methods for identification of studies
See: Colorectal Cancer Group methods used in reviews.
We searched the following electronic databases
- Cochrane Central Register of Controlled Trials
- ISI Web of Science (Science Citation Index, Current Contents)
from 1975 until June 2012
- Embase.com
- Pubmed
Electronic database searches were performed with MeSH terms
and free text terms:
-MeSH: \Rectal Neoplasms“[MeSH] AND\
Radiotherapy”[MeSH] AND \Drug Therapy“[MeSH]
-Free text terms:
rectal, rectum, cancer, adenocarcinoma, neoplasm, radiotherapy,
irradiation, chemotherapy, chemoradiation, radiochemotherapy,
combined modality, multimodal, preoperative, neoadjuvant
Manual search/abstract search
- Journals from 1990: Ann Surg, Arch Surg, Cancer, J Clin Oncol,
Int J Radiat Oncol Biol Phys
- Proceedings from ASTRO, ECCO and ASCO
No language constraints were applied.
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Data collection and analysis
All three reviewers obtained the full text of all relevant studies
and these were assessed for methodological quality according to
the Cochrane Collaboration’s tool for assessing the risk of bias
(Higgins 2011). Methodological details relevant for potential bias
included sequence generation, allocation concealment, blinding,
incomplete outcome data, and selective outcome reporting. Dis-
agreement was resolved by consensus.
Data were extracted by one reviewer (KF) on custom designed
forms and entered in a computer database for transfer and statis-
tical analysis in the Review Manager software. The data extracted
included first author, year of publication, source, method of pre-
operative therapy and surgery, method of randomization, number
of patients included, randomized, and analysed, and outcome pa-
rameters as listed above. Data accuracy was verified by the senior
author (WPC).
RT dose was converted to the biologically equivalent dose (BED)
using the linear quadratic equivalent formula (Dale 2005): BED
= nd(1+1/(α/β)-(γ /α)(T-Tk ), with n = number of fractions, d
= dose per fraction, α/β = the linear quadratic quotient (set at
10 Gy), γ /α= repair rate (set at 0.6 Gy/d), and Tk = the initial
time delay in days (set at 7). Differences between categorical out-
come parameters were quantified using the odds ratio (OR) and
corresponding 95% confidence interval (95CI). Summary statis-
tics were calculated using the Mantel-Haenszel methods. Het-
erogeneity analysis was performed using the Q test, with signifi-
cance accepted when P<0.1. When present, heterogeneity was ad-
dressed as recommended by the Cochrane Collaboration Hand-
book (Higgins 2011).
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of ongoing
studies.
The initial searchwas performed in June 2007. Of a total of 17925
studies resulting from the primary search, 324 papers were selected
for full review. In all, 320 papers were discarded (Table 1). Four
randomized trials were identified comparing preoperative RTwith
preoperative CRT in resectable stage II or III rectal cancer (Bosset
2006; Boulis-Wassif 1984; Bujko 2006; Gerard 2006). The search
was repeated, using similar criteria, in June 2012. A total of 1041
abstracts was selected and scrutinized, resulting in addition of one
randomized trial (Latkauskas 2011) to the search results.
Boulis-Wassif 1984: From November 1972 through April 1976,
Boulis-Wassif et al. recruited 247 patients with histologically
proven localized adenocarcinoma of the rectum and no clinical of
surgical evidence of distant metastases. All patients in both groups
received preoperative RT by two parallel opposing diamond and
chimney fields. All patients received a total dose of 34.5 Gy in 15
fractions of 2.3 Gy each over a total treatment time of 18 days
(BED = 35.8 Gy). In the preoperative CRT group, intravenous
5-FU injection (375 mg/m2) was administered during the first 4
days of irradiation. Surgery usually followed within 2 weeks af-
ter the last irradiation. Two patients died before surgery. Assessed
outcomes included ease of surgery, type of operation, radical re-
sectability rate, histopathological response, postoperative mortal-
ity, postoperative period of hospitalizations, local control of the
disease, distant metastases, disease free survival, and median sur-
vival. Follow-up was available up to 7 years.
Bujko 2006: FromApril 1999 until February 2002, Bujko et al. in-
cluded 316 patients with resectable T3-T4 rectal carcinoma with-
out sphincter infiltration and with a lesion accessible to digital
rectal examination. Patients were randomised to either preopera-
tive 5 x 5 Gy short-term RT (BED = 37.5 Gy) with subsequent
total mesorectal excision (TME) performed within 7 days or to
CRT to a total dose of 50.4 Gy (1.8 Gy per fraction during 25
days; BED = 42.2 Gy) concomitantly with two courses of bolus 5-
fluorouracil (325 mg/m2) and leucovorin during weeks 1 and 5 of
RT. Chemoradiation was followed by TME after 4-6 weeks. Three
patients did not undergo surgery. Assessed outcomes were acute
postirradiation toxicity, sphincter preservation rate, postoperative
mortality, pathology, overall survival, disease free survival, local
recurrence rate, distant metastases, late toxicity and incidence of
permanent stoma. Median follow up was 48 months.
Gerard 2006: Between April 1993 and November 2003, Gerard
et al. recruited 762 patients with a histologically confirmed, previ-
ously untreated rectal adenocarcinoma accessible to digital rectal
examination (T3 or resectable T4 tumour with no evidence of
distant metastases). Patients were allocated to two treatment arms:
preoperative RT vs. preoperative CRT, both followed by surgery.
RTwas delivered with photons from a linear accelerator in a three-
or four-field box technique. The dose per fraction was 1.8 Gy
and all fields were treated each day with five fractions per week.
The total dose was 45 Gy in 25 fractions during 5 weeks (BED
= 42.2 Gy). Concurrent chemotherapy (CT) consisted of bolus
5-fluorouracil (350 mg/m2) and leucovorin administered during
week 1 and 5 of RT. Surgery was planned between 3 and 10 weeks
after the end of the preoperative RT (+/- CT). TME was recom-
mended. Assessed outcomes were surgical procedures and postop-
erative complications, pathology, overall survival, progression free
survival, and local recurrence. Median follow-up was 81 months.
Bosset 2006: Between April 1993 and March 2003, Bosset et al.
recruited 1011 patients with a T3 or resectable T4 M0 adenocar-
cinoma of the rectum within 15 cm from the anal margin and
without previous treatment for this disease (EORTC 22921 trial).
Patients were allocated to four treatment arms: preoperative RT,
preoperative CRT, preoperative RT plus postoperative CT and
preoperative CRT plus postoperative CT. Radiotherapy consisted
of 45 Gy delivered to the posterior pelvis in 25 fractions of 1.8 Gy
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over a period of 5 weeks (BED = 42.2 Gy). The target volume of
RT was not a classical pelvic volume but was limited to the main
field of tumour spread and to the perirectal nodes. Preoperative
chemotherapywas delivered in two 5-day courses of 5-fluorouracil
(350 mg/m2) with leucovorin during the first and fifth weeks of
RT. Surgery was scheduled to take place 3 to 10 weeks after treat-
ment. TME was recommended beginning in 1999. Assessed out-
comes were toxicity of the preoperative treatment, surgical proce-
dures performed, rate of postoperative complications, pathology,
late side effects, overall survival, disease free survival, and local and
distant recurrence rate. Median follow-up of 5.4 years.
Latkauskas 2011: Latkauskas et al. evaluated 145 patients with his-
tologically proven rectal cancer between 2007 and 2010. Eighty-
three patients were e legible and randomized to receive either short
term radiotherapy (5x5 Gy, N=37) or CRT (50 Gy in 25 frac-
tions with 5-fluorouracil, N=46). In both groups, surgery was per-
formed after a 6 weeks waiting period. Sample size was based on
downstaging rate as primary endpoint; other endpoints were not
defined. The included paper reports on preliminary data (surgical
and pathological outcome).
Risk of bias in included studies
Randomisation was adequately performed in four studies using
communication with a central office; the study by Latkauskas et
al. does not specify the randomization method used. Three studies
based randomisation on the minimization method (Bujko 2006;
Gerard 2006; Bosset 2006). In the fourth study, the randomisa-
tion method is not specified (Boulis-Wassif 1984). None of the
studies were described as double blind or used blinded outcome
assessment. Description of withdrawals and dropouts was given
in four out of five studies. There were no imbalances between
treatment arms in the number of patients that did not undergo
the complete trial procedure. Three studies were performed on an
intention-to-treat basis (Bujko 2006; Gerard 2006; Bosset 2006);
no imbalances were identified between treatment arms.
Effects of interventions
The main primary outcome parameter was the local recurrence
rate at five years, which was reported in three studies (Bosset 2006;
Boulis-Wassif 1984; Gerard 2006). In the RT group, 122 of 740
patients (16.5%) developed a local recurrence while in the CRT
group this event was observed in 71 out of 754 patients (9.4%).
(Figure 1, Figure 2) This difference was statistically significant
(OR 0.53, 95%CI 0.39-0.72, P < 0.001). No statistically signif-
icant heterogeneity among studies was present (P = 0.12). Sur-
vival data at 5 years were available in three studies (Bosset 2006;
Boulis-Wassif 1984; Gerard 2006). In the CRT group, 644 of
1007 patients (63.9%) were alive at 5 years while in the RT group
647 of 993 patients (65.2%) survived 5 years. (Figure 3, Figure
4) This difference did not reach statistical significance (OR 0.95,
95%CI 0.79-1.14, P = 0.58). No heterogeneity was present (P =
0.15).
The results of the analysis of the secondary outcome parameters
were as follows. Disease free survival at 5 years, available in the
studies of Bosset 2006 and Gerard 2006, was 507/881 (57.5%)
in the CRT group and 479/872 (54.9%) in the RT group. This
difference was not statistically significant (OR 1.11, 95%CI 0.92-
1.34, P = 0.27). (Figure 5, Figure 6) Significant heterogeneity did
not occur (P = 0.64). Grade III or IV treatment related toxicity de-
veloped in 151 of 1015 patients (14.9%) treated with CRT while
in patients treated with RT alone, this occurred in 52 of 1017
patients (5.1%). (Figure 7) This difference was statistically signif-
icant (OR 4.1, 95%CI 1.68-10, P = 0.002). There was, however,
significant heterogeneity (P = 0.005) which remained when the
data were reanalysed using the random effects assumption. Among
patients who underwent surgery, sphincter preservation was pos-
sible in 583 of 1157 patients (50.4%) in the CRT group and in
553 of 1145 patients (48.3%) in the RT group; this difference
failed to reach statistical significance (OR 1.09, 95%CI 0.92-1.30,
P = 0.32). (Figure 8) No heterogeneity was observed (P = 0.48).
Postoperative 30 day mortality was observed in 31 of 1122 (2.8%)
patients in th CRT group and in 21 of 1117 (1.9%) patients in
the RT group. This difference did not reach statistical significance
(OR 1.48, 95%CI 0.84-2.6, P = 0.17); no heterogeneity was de-
tected (P = 0.6).Figure 9 Postoperative morbidity was marginally
higher in the CRT group (OR 0.67-1.00, P = 0.05) (Figure 10)
while no differences in anastomotic leak rate were detected (OR
0.62-1.84, P = 0.81). (Figure 11) Pathological complete response
(i.e., ypT0N0) of the resected specimen was observed in 135 of
1142 patients (11.8%) in the CRT group and in 40 of 1142 pa-
tients (3.5%) in the RT group. (Figure 12) This difference was
statistically significant (OR 3.52, 95%CI 2.12-5.84, P < 0.00001)
while significant heterogeneity for this parameter was not observed
(P = 0.25).
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Figure 1. Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.10 Local Recurrence
at 5y.
Figure 2. Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.12 HR˙LR.
Figure 3. Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.1 Overall Survival at
5y.
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Figure 4. Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.2 HR˙OS.
Figure 5. Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.3 Disease free
survival at 5 y.
Figure 6. Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.11 HR˙DFS.
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Figure 7. Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.6 Grade III - IV
toxicity.
Figure 8. Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.7 Sphincter
preservation.
Figure 9. Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.4 Mortality 30 d.
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Figure 10. Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.5 Postop morbidity.
Figure 11. Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.9 Anastomotic
leak.
Figure 12. Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.8 pCR.
Because of the limited number of included studies, no sensitivity
analysis was performed. D I S C U S S I O N
Preoperative RT has been shown to reduce local recurrence rates
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and marginally improve survival over surgery alone provided a
BED > 30 Gy is delivered to the target region (Gray 2001). The
current review addresses the question whether the addition of che-
motherapy to preoperative RT further improves pathological and
clinical outcome parameters. Five randomized trials were identi-
fied comparing preoperative CRT with preoperative RT alone in
resectable, locally advanced rectal cancer. Although there was con-
siderable variation in radiotherapy dose and fractionation, all five
studies have used a BED > 30 Gy. In three trials (Gerard 2006;
Boulis-Wassif 1984; Bosset 2006), RT regimens were identical in
both groups. The study by Latkauskas et al. compared two dif-
ferent regimens, but with a similar interval to surgery (Latkauskas
2011). In the Polish study (Bujko 2005, Bujko 2006), RTdose and
fractionation as well as time interval until surgery were different in
both groups (5x5 Gy followed by immediate surgery versus 50.4
Gy with chemotherapy followed by surgery after a waiting period
of 4-6 weeks). In this study, therefore, it remains unclear whether
the observed differences in tumour response between both arms
are attributable to the addition of chemotherapy or to a different
RT schedule and a different waiting period until surgery. Since,
moreover, actuarial local recurrence data at five years are not avail-
able in this study, it was left out from the meta-analysis of local
recurrence at five years. This analysis demonstrates a significant re-
duction in local recurrence rate with the addition of chemotherapy
(OR0.39-0.72, P < 0.001). Importantly, the cumulative incidence
rates of local recurrence in the RT group of the studies of Bosset
2006 and Gerard 2006 (17%) and in both groups of the study of
Boulis-Wassif 1984 (15%) seem high compared to the 5.5% local
recurrence rate at five years achieved by the Dutch rectal cancer
trial using 5x5 Gy preoperative RT followed by surgery (van den
Brink 2004). Differences in stage distribution and variation in
surgical technique might explain this observation. Indeed, during
the Dutch rectal cancer trial a formal surgical training and qual-
ity control program was implemented in order to guarantee op-
timal surgery (TME). The study of Boulis-Wassif 1984 predated
the introduction of TME surgery (inclusion period 1972-1976),
whereas in the studies of Bosset 2006 and Gerard 2006, TME
surgery was ’recommended’ without any formal surgical training
or quality control.
Although in the study of Boulis-Wassif 1984 a marginally signifi-
cant five year survival benefit was associated with CRT, the com-
bined analysis failed to demonstrate a significant difference in ei-
ther overall or disease free survival at five years (OR 0.79-1.14, P
= 0.58 and OR 0.92-1.34, P = 0.27, respectively). One of the hy-
potheses formulated to explain the observed lack of survival bene-
fit found in many pre- or postoperative adjuvant therapy trials in
rectal cancer is the existence of early, subclinical systemic disease
present at diagnosis. This hypothesis is supported by the finding
that the rate of distant metastatic disease in all four trials is consis-
tently around 30%, without any difference between CRT and RT
groups, indicating a future role of more effective systemic ther-
apy to eradicate micrometastatic disease from the onset of therapy.
Others have argued that the follow up time of the included trials
is too short to observe a survival benefit, or that the incidence of
local recurrence is too low to influence survival (Gerard 2006).
Grade III and IV acute treatment related toxicity was more pro-
nounced in the CRT group in the three studies reporting this pa-
rameter (Bosset 2006; Bujko 2006; Gerard 2006), with an overall
OR of 1.68-10 and a P value of 0.002. However, chemotherapy
related toxicity was generally acceptable as evidenced by the high
compliance rates in the studiesmentioned (82%, 78.1%, and 69%
respectively). In resected patients, no differences were observed in
30 day mortality or anastomotic leak rate, but a marginally sig-
nificant difference in overall postoperative morbidity was found.
The results concerning anastomotic leakage should be interpreted
with caution, since the exceedingly low leakage rate in the study
of Bosset compared to currently accepted and published leakage
rates following anterior resection suggests underreporting of this
specific complication.
Postoperative quality of life (QoL) is an important, though of-
ten underreported aspect of cancer trials. From the Swedish and
Dutch rectal cancer trials, it is known that preoperative 5x5 Gy
followed by surgery significantly worsens functional outcome in
terms of bowel, sexual, and bladder function compared to surgery
alone (Holm 1996; Dahlberg 1998; Peeters 2005). A number of
phase II trials have suggested that preoperative CRT followed by
surgery does not adversely affect functional outcome (Feliu 2002;
Bosset 2000). The scarce available data in the four included stud-
ies did not allow to perform a meta-analysis of QoL related pa-
rameters. However, preliminary functional outcome data of the
EORTC 22921 study (published as abstract only) demonstrated a
significantly worse anorectal function in CRT patients compared
to RT alone (Mercier 2005). Interestingly, in the final results pa-
per of this study the incidence of ’late side effects’ including fecal
incontinence did not seem to differ between the four treatment
arms (Bosset 2006).
The results of the meta-analysis confirm the enhanced cytotoxic
efficacy of combined RT with 5-fluorouracil based chemother-
apy. The incidence of a complete pathological response (pCR,
ypT0N0) was 135 of 1142 patients (11.8%) in the CRT group
and 40 of 1142 patients (3.5%) in the RT group; this difference
was statistically highly significant (OR 3.52, 95%CI 2.12-5.84,
P < 0.00001) while no heterogeneity was observed between the
four studies. The results of the EORTC studymoreover confirmed
the difference in radioresponsiveness of the tumour in the bowel
wall compared to that of mesorectal lymph nodes, as evidenced
by nodal involvement in up to 12% of ypT0 patients (Bosset
2004). Although in two studies (Bosset 2006; Boulis-Wassif 1984)
a trend towards increased sphincter preservation was observed in
the CRT group, the overall results failed to demonstrate an in-
crease in sphincter preserving surgery following CRT notwith-
standing the downsizing and downstaging effect often noted with
the combined therapy. This finding may be related to reluctance
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of the colorectal surgeon to alter a preoperative assessment of the
need to perform a rectal amputation, since reversal of this decision
would possibly imply performing an anastomosis in previously
macroscopically invaded tissue. Moreover, in at least two studies
it was specifically advised not to change a preoperative decision to
perform a rectal amputation even after a significant downsizing.
Data from the German rectal cancer trial, however, suggested that
a change in operative strategy (i.e., perform sphincter preserving
surgery when a significant clinical response is observed) may be
safely performed. Longer follow up will be needed to confirm the
safety of this approach. Mature results (including recurrence and
survival data) from the study by Latkauskas et al. are awaited. An
ongoing study by the Berlin Cancer Society, randomises patients
with histologically proven rectal cancer staged T2N+ or T3 to re-
ceive either SCRT (25 Gy in five fractions of 5 Gy) plus TME-
surgery within 5 days or CRT (50.4 Gy in 28 fractions of 1.8 Gy,
continuous infusion 5-fluorouracil) plus TME-surgery 4-6 weeks
later (Siegel 2009). All patients receive adjuvant chemotherapy
(12 weeks continuous infusional 5-FU) and are followed up for 5
years. TME-quality is independently documented by the surgeon
and the pathologist; the primary endpoint is local recurrence at
five years.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Compared to preoperative RT alone, preoperative CRT enhances
tumour response and improves local recurrence rates. The addition
of chemotherapy causes a moderate increase in acute toxicity and
overall postoperativemorbidity, although anastomotic leakage rate
or 30 day mortality are not enhanced. At this moment, it is unclear
from the available data whether the addition of chemotherapy to
preoperative RT influences sphincter preservation. Patients should
be informed about the possible functional andQoL related aspects
of preoperative therapy.
Implications for research
1. Since the improvement of local control obtained with CRT did
not translate into a better overall or disease free survival and up to
one third of all patients develop distant spread, priority should be
given to trials addressing early subclinical systemic spread;
2. Trials are needed that specifically address the oncological safety
of performing sphincter preserving surgery (including intersphinc-
teric resection and colo-anal anastomosis) in patients deemed to
require amputation before the start of CRT and in whom a sig-
nificant clinical response is observed;
3. Preoperative therapy trials in rectal cancer should include formal
evaluation of functional and QoL related aspects of therapy.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bosset 2006
Methods 1.Randomization method: telephone to central office (assumed)
2. Abdominal imaging: CT
3. Chest imaging: CXR
4. 4 arm study: Arm 1 preop RT + S; Arm 2 preop XRT + concurrent 5FU LV + S;Arm 3
preop RT + S + post op 5FU LV ; Arm 4 preop RTCT+ S + postop 5FU LV
5. Total randomized 1011
Participants 1. Rectal Cancer
2. Location: within 15 cm from anal verge
3. Resectability: locally resectable
4. T3 or resectable T4 (defined by clinical criteria or endoscopic ultrasound)
5. WHO PS 0-1
6. </=80yr
Interventions 1.Surgery: AP/anterior resection or Hartman with TME
2. RT : 45 Gy in 25fr.
3. RT volume: 5cm above and below tumour and perirectal nodes below S2-3. If tumour
above 10cm, include
only 3 cm above tumour. If tumour in low rectum, S2-3 to perineum. Posteriorly to include
entire sacrum with 3cm beyond macroscopic extension
4. RT-S: within 3-10 weeks of completing neoadjuvant therapy
5. 3 or 4 field
6. Chemotherapy: 5FU 325mg/m2/d; Leucovorin 20mg/m2/day Dy1-5 & 28-32 for arms
2 and 4, and
postoperative for arms 3 and 4
Outcomes 1. Duration of FU: 5.4 yrs
2. Perioperative mortality: CRTS 2.4 % (12/506) RTS 1.2% (6/505)
3. Mets (liver) @ lap: Y
4. Curative resection: not stated
5. Overall resection: 94.5 %
6. Compliance to radiotherapy: CRTS 483/506 (95.5%) RTS 495/505 (98.0%)
7. OAS: Y
8. CSS?
9. Tox post RT: Y
10. Acute tox post S: Y
11. Late tox post S: Y
12. LR: Y
13. QOL: N
14. Proportion sfincter sparing: CRTS 267/506 (52.8%) RTS 255/505 (50.5%)
15. Proportion downstaging: Y
Notes
Risk of bias
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Bosset 2006 (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
Boulis-Wassif 1984
Methods 1.Randomization method: not stated. conducted by cooperative group. Likely via central
office
2. Abdominal imaging: Not stated
3. Chest imaging: Not stated
4. Study arm (Preop chemoradiotherapy arm) : 171randomized, 45 excluded.
5. Control arm (Preop radiotherapy arm): 168 randomized , 47 excluded
Participants 1. Rectal Cancer
2. Location: below within 15cm anal verge
3. Resectability: fit for surgery
Interventions 1.Surgery: AP/anterior resection
2. RT : 3450 cGy in 15fr. (for both arms)
3. BED: 35.2Gy1
4. RT volume: ”chimney and diamond fields“ paraaortic and pelvis.
5. RT-S: within 2 wk
6. 2 field
7. Cointervention: none
8. 2 arms, control (Radiotherapy followed by surgery), Study (Chemoradiotherapy followed
by surgery)
9.Chemotherapy: 5FU 10mg/kg/d day 1-4
Outcomes 1.Duration of FU: mean 5.2yrs
2. Perioperative mortality: CRTS 19/126 RTS 11/121
3. Mets @ lap: CRTS 13/126 RTS 15/121
4. Curative resection: Not stated
5. Overall resection: CRTS 121, RTS 124
6. Compliance to radiotherapy: not given
7. OAS: Y
8. CSS: N
9. Tox post RT: not given
10: Acute tox post S: not given
No complication not given
11. Late tox post S: not given
12: LR: N
13. QoL:N
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Boulis-Wassif 1984 (Continued)
Allocation concealment (selection bias) Low risk A - Adequate
Bujko 2006
Methods 1.Randomization method: telephone to central office
2. Abdominal imaging: ultrasound or CT
3. Chest imaging: CXR
4. XRT + S arm : (short XRT)155 randomized, 0 excluded.
5. Arm B: (Long XRT+CT): 157 randomized , 0 excluded
Participants 1. Rectal Cancer
2. Location: inferior edge palpable of digital exam
3. Resectability: locally resectable
4. T3 or resectable T4
5. not involving sphincter
Interventions 1.Surgery: AP/anterior resection or Hartman with TME
2. RT : XRT +S arm: 2500cGy cGy in 5fr. ; Arm B: 50.4Gy in 28 fr with concomitant CT
weeks 1 & 5
3. BED: Arm A 38.7Gy10, Arm B 40.9Gy10
4. RT volume: Not stated
5. RT-S: XRT+S within 7 days; Arm B: within 4-6 weeks
6. 3 or 4 field
7. Arm B chemotherapy: 5FU 325mg/m2/d; Leucovorin 20mg/m2/day Dy1-5 & 28-32
Outcomes 1.Duration of FU: not stated
2. Perioperative mortality: XRT+S 0/155 Arm B 0/157
3. Mets @ lap: not stated
4. Curative resection: not stated
5. Overall resection: XRT+S 145/155 Arm B 147/157
6. Compliance to radiotherapy: XRT+S 152/155 Arm B 141/157
7. OAS: N
8. CSS: N
9. Tox post RT: no complications XRT+S 118/155 Arm B 24/157 Any complications
XRT+S 37/155 Arm
B 133/157 Gd 3-4 XRT + S 5/155 Arm B 26/157 Gd 5 (Death) XRT +S 0/155 Arm B 2/
157
10: Acute tox post S: Not stated
11. Late tox post S: not given
12: LR: N
13. QoL:N
14. Proportion sphincter sparing
15. Proportion downstaged (by T stage, N stage, Tumor size)
Notes
Risk of bias
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Bujko 2006 (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
Gerard 2006
Methods 1.Randomization method: not stated
2. Abdominal imaging: liver sonography - CT scan
3. Chest imaging: CXR
4. Study arm: CRT 375
5. Control arm: RT 367
Participants 1. Rectal Cancer
2. Location: accessible by digital examination
3. Resectability: locally resectable
Interventions 2 arms: preop XRT vs preop CRT
1.Surgery: TME recommended
2. RT 45Gy in 25 fr for both arms
3. BED: 32.5Gy10
4. RT volume: NA
5. RT-S: NA
6. NA
7. Cointervention: postoperative CT (5FU FA) x 4 cycles
Outcomes 1.Duration of FU: 81m
2. Perioperative mortality (60 days): 2% for both arms
3. Mets @ lap: not stated
4. Curative resection: not stated
5. Overall resection: not stated
6. Compliance to radiotherapy: not stated
7. OAS: Y
8. CSS: Y
9. Tox (gr 3-4) post RT: Preop RT arm: 10/367 CRT arm: 55/375
10: Acute tox post S: not stated
11. Late tox post S: Y
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
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Latkauskas 2011
Methods 1. Randomization method: not stated
2. Abdominal imaging: abdominal US, EUS, CT scan and MRI pelvis
3. Chest imaging: CXR
4. Study arm: CRT 46
5. Control arm: RT 37
Participants 1. Rectal cancer stage II and III
2. less than 15 cm from anal verge
3. <80 years old, no other cancer during last 5 years
Interventions 1. CRT: 50 Gy in 25 fractions, 1.8-2 Gy/fraction over 5 weeks with 5-FU/LV during week
1 and 5
2. RT: 25 Gy in 5 fractions
3. Surgery: after 6 weeks in both groups
Outcomes 1. Duration of FU: not stated
2. Perioperative mortality: not stated
3. Mets @ lap: not stated
4. Curative resection: 91.3% (CRT), 86.5% (RT)
5. Overall resection: 37/37 (RT), 46/46 (CRT)
6. Compliance to radiotherapy: not stated
7. OAS: not stated
8. CSS: not stated
9. Tox (gr 3-4) post RT: not stated
10: Acute tox post S: not stated
11. Late tox post S: not stated
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk
Characteristics of ongoing studies [ordered by study ID]
Siegel 2009
Trial name or title Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer:
a multi-centre prospectively randomised study of the Berlin Cancer Society
Methods Prospective Randomized trial
Participants Primary rectal cancer within 12 cm from anal verge, cT3N+, cT3N0, or cT2N+
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Siegel 2009 (Continued)
Interventions Short course RT consists of single doses of 5.0 Gy in five fractions within one week up to a total dose of 25 Gy.
For CRT, standard fractions of 1.8 Gy/d are given 5 times a week up to a total dose of 50.4 Gy; concomitant
chemotherapy consists of continuous 5-FU-infusion 225 mg per square meter per day
Outcomes Local recurrence after five years follow up has been chosen as primary endpoint
Starting date 2008
Contact information Peter M Schlag email: pmschlag@charite.de
Department of Surgery and Surgical Oncology, Charité - Universitätsmedizin Berlin, Berlin, Germany
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. radiotherapy vs radiochemotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall Survival at 5y 3 2000 Odds Ratio (M-H, Fixed, 95% CI) 1.05 [0.88, 1.27]
2 HR˙OS 4 0 Hazard Ratio (95% CI) 1.02 [0.89, 1.17]
3 Disease free survival at 5 y 2 1753 Odds Ratio (M-H, Fixed, 95% CI) 0.90 [0.74, 1.09]
4 Mortality 30 d 5 2322 Odds Ratio (M-H, Random, 95% CI) 1.48 [0.83, 2.63]
5 Postop morbidity 4 2077 Odds Ratio (M-H, Random, 95% CI) 0.82 [0.67, 1.00]
6 Grade III - IV toxicity 3 2032 Odds Ratio (M-H, Random, 95% CI) 4.10 [1.68, 10.00]
7 Sphincter preservation 5 2302 Odds Ratio (M-H, Random, 95% CI) 1.09 [0.92, 1.30]
8 pCR 5 2284 Odds Ratio (M-H, Random, 95% CI) 3.52 [2.12, 5.84]
9 Anastomotic leak 4 1151 Odds Ratio (M-H, Random, 95% CI) 1.07 [0.62, 1.84]
10 Local Recurrence at 5y 3 1494 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.39, 0.72]
11 HR˙DFS 4 0 Hazard Ratio (95% CI) 0.99 [0.84, 1.17]
12 HR˙LR 3 0 Hazard Ratio (95% CI) 0.71 [0.52, 0.95]
Analysis 1.1. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 1 Overall Survival at 5y.
Review: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
Comparison: 1 radiotherapy vs radiochemotherapy
Outcome: 1 Overall Survival at 5y
Study or subgroup CRT RT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Boulis-Wassif 1984 68/126 50/121 10.6 % 1.66 [ 1.01, 2.75 ]
Gerard 2006 122/375 118/367 36.4 % 1.02 [ 0.75, 1.38 ]
Bosset 2006 173/506 178/505 53.0 % 0.95 [ 0.74, 1.24 ]
Total (95% CI) 1007 993 100.0 % 1.05 [ 0.88, 1.27 ]
Total events: 363 (CRT), 346 (RT)
Heterogeneity: Chi2 = 3.78, df = 2 (P = 0.15); I2 =47%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 2 HR˙OS.
Review: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
Comparison: 1 radiotherapy vs radiochemotherapy
Outcome: 2 HR˙OS
Study or subgroup CRT RT Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
Bosset 2006 0/0 0/0 45.4 % 1.02 [ 0.83, 1.26 ]
Boulis-Wassif 1984 0/0 0/0 15.0 % 1.16 [ 0.80, 1.66 ]
Bujko 2006 0/0 0/0 13.8 % 0.99 [ 0.68, 1.45 ]
Gerard 2006 0/0 0/0 25.8 % 0.96 [ 0.73, 1.27 ]
Total (95% CI) 100.0 % 1.02 [ 0.89, 1.17 ]
Heterogeneity: Chi2 = 0.66, df = 3 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Analysis 1.3. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 3 Disease free survival at 5 y.
Review: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
Comparison: 1 radiotherapy vs radiochemotherapy
Outcome: 3 Disease free survival at 5 y
Study or subgroup CRT RT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gerard 2006 152/375 163/367 43.1 % 0.85 [ 0.64, 1.14 ]
Bosset 2006 222/506 230/505 56.9 % 0.93 [ 0.73, 1.20 ]
Total (95% CI) 881 872 100.0 % 0.90 [ 0.74, 1.09 ]
Total events: 374 (CRT), 393 (RT)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
21Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.4. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 4 Mortality 30 d.
Review: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
Comparison: 1 radiotherapy vs radiochemotherapy
Outcome: 4 Mortality 30 d
Study or subgroup CRT RT Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bosset 2006 12/487 6/483 33.7 % 2.01 [ 0.75, 5.40 ]
Boulis-Wassif 1984 11/124 6/121 31.2 % 1.87 [ 0.67, 5.22 ]
Bujko 2006 1/152 2/153 5.7 % 0.50 [ 0.04, 5.57 ]
Gerard 2006 7/359 7/360 29.4 % 1.00 [ 0.35, 2.89 ]
Latkauskas 2011 0/46 0/37 Not estimable
Total (95% CI) 1168 1154 100.0 % 1.48 [ 0.83, 2.63 ]
Total events: 31 (CRT), 21 (RT)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.86, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
22Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.5. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 5 Postop morbidity.
Review: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
Comparison: 1 radiotherapy vs radiochemotherapy
Outcome: 5 Postop morbidity
Study or subgroup CRT RT Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bosset 2006 111/487 112/483 46.2 % 0.98 [ 0.73, 1.32 ]
Bujko 2006 31/152 39/153 14.3 % 0.75 [ 0.44, 1.28 ]
Gerard 2006 75/359 97/360 34.7 % 0.72 [ 0.51, 1.01 ]
Latkauskas 2011 12/46 15/37 4.8 % 0.52 [ 0.20, 1.31 ]
Total (95% CI) 1044 1033 100.0 % 0.82 [ 0.67, 1.00 ]
Total events: 229 (CRT), 263 (RT)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.98, df = 3 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 6 Grade III - IV toxicity.
Review: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
Comparison: 1 radiotherapy vs radiochemotherapy
Outcome: 6 Grade III - IV toxicity
Study or subgroup CRT RT Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bosset 2006 67/483 37/495 38.4 % 1.99 [ 1.31, 3.04 ]
Bujko 2006 29/157 5/155 28.0 % 6.80 [ 2.56, 18.07 ]
Gerard 2006 55/375 10/367 33.6 % 6.14 [ 3.08, 12.24 ]
Total (95% CI) 1015 1017 100.0 % 4.10 [ 1.68, 10.00 ]
Total events: 151 (CRT), 52 (RT)
Heterogeneity: Tau2 = 0.49; Chi2 = 10.57, df = 2 (P = 0.01); I2 =81%
Test for overall effect: Z = 3.10 (P = 0.0019)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 7 Sphincter preservation.
Review: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
Comparison: 1 radiotherapy vs radiochemotherapy
Outcome: 7 Sphincter preservation
Study or subgroup CRT RT Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bosset 2006 263/473 249/475 45.0 % 1.14 [ 0.88, 1.47 ]
Boulis-Wassif 1984 13/124 6/121 2.9 % 2.24 [ 0.82, 6.11 ]
Bujko 2006 87/157 87/155 14.7 % 0.97 [ 0.62, 1.52 ]
Gerard 2006 188/357 185/357 34.1 % 1.03 [ 0.77, 1.39 ]
Latkauskas 2011 32/46 26/37 3.3 % 0.97 [ 0.38, 2.49 ]
Total (95% CI) 1157 1145 100.0 % 1.09 [ 0.92, 1.30 ]
Total events: 583 (CRT), 553 (RT)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.54, df = 4 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 8 pCR.
Review: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
Comparison: 1 radiotherapy vs radiochemotherapy
Outcome: 8 pCR
Study or subgroup CRT RT Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bosset 2006 60/473 22/476 43.6 % 3.00 [ 1.81, 4.97 ]
Boulis-Wassif 1984 6/126 3/121 11.1 % 1.97 [ 0.48, 8.05 ]
Bujko 2006 22/138 1/148 5.8 % 27.88 [ 3.70, 209.90 ]
Gerard 2006 41/359 13/360 34.4 % 3.44 [ 1.81, 6.54 ]
Latkauskas 2011 6/46 1/37 5.1 % 5.40 [ 0.62, 47.03 ]
Total (95% CI) 1142 1142 100.0 % 3.52 [ 2.12, 5.84 ]
Total events: 135 (CRT), 40 (RT)
Heterogeneity: Tau2 = 0.09; Chi2 = 5.44, df = 4 (P = 0.25); I2 =26%
Test for overall effect: Z = 4.88 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 9 Anastomotic leak.
Review: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
Comparison: 1 radiotherapy vs radiochemotherapy
Outcome: 9 Anastomotic leak
Study or subgroup CRT RT Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bosset 2006 2/267 0/255 3.2 % 4.81 [ 0.23, 100.71 ]
Bujko 2006 8/87 9/86 29.5 % 0.87 [ 0.32, 2.36 ]
Gerard 2006 14/188 14/185 50.0 % 0.98 [ 0.45, 2.12 ]
Latkauskas 2011 7/46 4/37 17.2 % 1.48 [ 0.40, 5.50 ]
Total (95% CI) 588 563 100.0 % 1.07 [ 0.62, 1.84 ]
Total events: 31 (CRT), 27 (RT)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.40, df = 3 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 10 Local Recurrence at 5y.
Review: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
Comparison: 1 radiotherapy vs radiochemotherapy
Outcome: 10 Local Recurrence at 5y
Study or subgroup CRT RT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bosset 2006 22/253 43/252 35.2 % 0.46 [ 0.27, 0.80 ]
Boulis-Wassif 1984 19/126 18/121 14.0 % 1.02 [ 0.51, 2.04 ]
Gerard 2006 30/375 61/367 50.8 % 0.44 [ 0.27, 0.69 ]
Total (95% CI) 754 740 100.0 % 0.53 [ 0.39, 0.72 ]
Total events: 71 (CRT), 122 (RT)
Heterogeneity: Chi2 = 4.24, df = 2 (P = 0.12); I2 =53%
Test for overall effect: Z = 4.03 (P = 0.000057)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 11 HR˙DFS.
Review: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
Comparison: 1 radiotherapy vs radiochemotherapy
Outcome: 11 HR˙DFS
Study or subgroup CRT RT Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
Bosset 2006 0/0 0/0 7.6 % 0.84 [ 0.46, 1.54 ]
Boulis-Wassif 1984 0/0 0/0 12.4 % 1.13 [ 0.70, 1.80 ]
Bujko 2006 0/0 0/0 24.3 % 1.04 [ 0.74, 1.46 ]
Gerard 2006 0/0 0/0 55.8 % 0.96 [ 0.77, 1.20 ]
Total (95% CI) 100.0 % 0.99 [ 0.84, 1.17 ]
Heterogeneity: Chi2 = 0.73, df = 3 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 12 HR˙LR.
Review: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
Comparison: 1 radiotherapy vs radiochemotherapy
Outcome: 12 HR˙LR
Study or subgroup CRT RT Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
Bosset 2006 0/0 0/0 34.1 % 0.69 [ 0.41, 1.15 ]
Bujko 2006 0/0 0/0 18.7 % 0.65 [ 0.33, 1.30 ]
Gerard 2006 0/0 0/0 47.1 % 0.74 [ 0.48, 1.15 ]
Total (95% CI) 100.0 % 0.71 [ 0.52, 0.95 ]
Heterogeneity: Chi2 = 0.12, df = 2 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 2.28 (P = 0.023)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. excluded studies
Type N
Non randomized trials 144
Adjuvant therapy trials 28
Trials not including at least one chemotherapy arm combinedwith
radiotherapy
71
Trials not including radiotherapy 27
Trials using local or no resection 18
Trials including other tumour types 25
Trials not including stage II/III cancer 7
Total 320
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WH A T ’ S N E W
Last assessed as up-to-date: 16 July 2012.
Date Event Description
25 January 2013 New search has been performed Review update with one new trial included
25 January 2013 New citation required but conclusions have not changed Review update with one new trial included
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Review first published: Issue 1, 2009
Date Event Description
26 February 2007 New citation required and conclusions have changed Substantive amendment
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